Aha: Mixed Results With Dapagliflozin In T2d Patients | Latest News RSS feed

Aha: Mixed Results With Dapagliflozin In T2d Patients - Latest News

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor ... Clinical trial results ... read more

Bristol-Myers Squibb CEO Discusses Q3 2013 Results - Earnings Call Transcript

Yervoy results in the U.S. were also positive, notwithstanding the impact of a significant number of new clinical trials targeting melanoma patients with other agents ... showed encouraging gains. And ... read more

AZN: 1st Quarter Results

Pascal Soriot, Chief Executive Officer, commenting on the results said: "We delivered a first-quarter ... In line with the strategy designed to deliver benefits to patients and value for shareholders, ... read more

Looking for another news?

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

Dapagliflozin has been shown to be effective in patients with early type 2 diabetes (i.e., treatment-naive patients), as well as in patients dependent on insulin plus insulin sensitizers. 62 A pooled ... read more

Dietary Supplements and Nutraceuticals

The molecular nutrition paradigm is predicated on foodome–metabolome network interactions. Dietary supplements and nutraceuticals (DSN) provide nutrient molecules in discrete amounts and oftentimes as ... read more

Dr. Deepak Bhatt

Dr. Deepak Bhatt is a cardiologist in Boston, Massachusetts and is affiliated with Brigham and Women's Hospital. He received his medical degree from Weill Cornell Medical College of Cornell University ... read more

Farxiga significantly reduced hospitalisation for

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin ... on CV outcomes in adults with T2D at risk of CV even... read more

Agalsidase-Beta Therapy for Advanced Fabry Disease

Desnick, PhD, MD; for the Fabry Disease Clinical Trial Study Group* Dr. Waldek ... Provision of study materials or patients: J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, M. McDonald, R. Finkel, S. ... read more

AstraZeneca's CEO Discusses Q4 2012 Results - Earnings Call Transcript

Welcome to our 2012 full-year results presentation ... In the fourth quarter, Brilinta was added to the ACCF/AHA guidelines for the management of patients with ST-elevation myocardial infarction eleva... read more

The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase ... of the largest trials in broad patient populations with Farxiga (dapagliflozin) ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us